Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs
Abstract
About the Authors
D. Yu. PlatonovRussian Federation
N. A. Tsareva
Russian Federation
S. N. Avdeev
Russian Federation
References
1. Легочная гипертензия. Под ред. И.Е.Чазовой и Т.В.Мартынюк. М.: Практика, 2015.
2. Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru
3. Galie N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67-119.
4. Alonzo G. et al. Survival in Patients with Primary Pulmonary Hypertension. Results from a National Prospective Registry. Ann Intern Med 1991; 115: 343-9.
5. Farber H.W. et al. Five-Year Outcomes of Patients Enrolled in the REVEAL Registry. Chest 2015; 148 (4): 1043-54.
6. Инструкция по применению лекарственного препарата для медицинского применения Траклир. ЛС-002509-310812
7. Channick R.N. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study. Lancet 2001; 358: 1119-23.
8. Rubin L.J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
9. McLaughlin V.V. et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-9.
10. Galiè N. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-100.
11. Simonneau G. et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol 2014; 172: 332-39.
12. Инструкция по медицинскому применению лекарственного препарата Опсамит. ЛП-003310-010916.
13. Pulido T. et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809-18.
14. Souza R. et al. Long-term survival and safety with macitentan in patients with pulmonary arterial hypertension: results from the seraphin study and its open-label extension. Am J Respir Crit Care Med 2017; 195: A2294 (Available at: http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A2294)
15. Инструкция по применению лекарственного препарата для медицинского применения Волибрис. ЛП001345 от 25.03.2016.
16. Galiè N. et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 2008; 117: 3010-9.
17. Oudiz R.J. et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: 1971-81.
18. Инструкция по применению лекарственного препарата для медицинского применения Ревацио. ЛП 000197-130514.
19. Galiè N. et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005; 353: 2148-57.
20. Rubin L.J. et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension. Chest 2011; 140 (5): 1274-83.
21. Инструкция по медицинскому применению лекарственного препарата Адемпас (от 05.10.2017).
22. Ghofrani H-A. et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330-40.
23. Rubin L.J et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1211-3.
24. Ghofrani H-A et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361-71 (http://dx.doi.org/10.1016/S2213-2600(16)30019-4)
25. Halank M et al. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respiratory Medicine 2017; 128: 50-6.
26. Huan-long Liu et al. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension. A Meta-analysis of Randomized Controlled Trials. Chest 2016; 150 (2): 353-66.
Review
For citations:
Platonov D.Yu., Tsareva N.A., Avdeev S.N. Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. Systemic Hypertension. 2017;14(3):58-64.
Email this article 